Collegium Pharmaceutical (NASDAQ:COLL) Rating Increased to Strong-Buy at Zacks Research

Collegium Pharmaceutical (NASDAQ:COLL) was upgraded by equities researchers at Zacks Research from a “hold” rating to a “strong-buy” rating in a report released on Monday,Zacks.com reports.

Other equities research analysts have also issued reports about the stock. Wall Street Zen upgraded shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Needham & Company LLC reissued a “buy” rating and issued a $56.00 price target (up from $54.00) on shares of Collegium Pharmaceutical in a report on Thursday, March 19th. HC Wainwright restated a “buy” rating and issued a $60.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday, March 20th. Truist Financial raised shares of Collegium Pharmaceutical to a “strong-buy” rating in a research note on Monday, June 15th. Finally, Weiss Ratings lowered shares of Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, March 5th. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Hold rating to the company. According to MarketBeat, Collegium Pharmaceutical presently has a consensus rating of “Buy” and a consensus target price of $57.50.

Collegium Pharmaceutical Trading Up 0.6%

NASDAQ:COLL opened at $36.20 on Monday. The stock’s fifty day moving average price is $34.17 and its two-hundred day moving average price is $39.45. The company has a debt-to-equity ratio of 2.47, a current ratio of 1.71 and a quick ratio of 1.62. Collegium Pharmaceutical has a 1 year low of $29.19 and a 1 year high of $50.79. The company has a market cap of $1.17 billion, a P/E ratio of 17.75 and a beta of 0.74.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 EPS for the quarter, topping the consensus estimate of $1.52 by $0.24. The company had revenue of $193.52 million during the quarter, compared to analyst estimates of $184.47 million. Collegium Pharmaceutical had a return on equity of 95.18% and a net margin of 9.41%.Collegium Pharmaceutical’s revenue was up 8.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.49 earnings per share. As a group, analysts expect that Collegium Pharmaceutical will post 6.76 EPS for the current year.

Institutional Investors Weigh In On Collegium Pharmaceutical

Several hedge funds have recently made changes to their positions in the company. Rubric Capital Management LP grew its stake in Collegium Pharmaceutical by 5.3% in the second quarter. Rubric Capital Management LP now owns 3,157,743 shares of the specialty pharmaceutical company’s stock worth $93,374,000 after purchasing an additional 157,743 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Collegium Pharmaceutical by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 2,256,254 shares of the specialty pharmaceutical company’s stock valued at $104,465,000 after buying an additional 29,876 shares in the last quarter. Janus Henderson Group PLC boosted its holdings in shares of Collegium Pharmaceutical by 26.0% during the 1st quarter. Janus Henderson Group PLC now owns 1,825,651 shares of the specialty pharmaceutical company’s stock valued at $60,358,000 after buying an additional 377,073 shares in the last quarter. Renaissance Technologies LLC grew its position in shares of Collegium Pharmaceutical by 1.1% in the 4th quarter. Renaissance Technologies LLC now owns 1,617,349 shares of the specialty pharmaceutical company’s stock worth $74,883,000 after buying an additional 18,160 shares during the period. Finally, Principal Financial Group Inc. increased its stake in shares of Collegium Pharmaceutical by 0.3% in the 4th quarter. Principal Financial Group Inc. now owns 1,313,662 shares of the specialty pharmaceutical company’s stock worth $60,823,000 after acquiring an additional 3,891 shares in the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.